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PLINICAL RESEARCH Clinical Trials
iventricular Versus Conventional Right
entricular Stimulation for Patients With Standard
acing Indication and Left Ventricular Dysfunction
he Homburg Biventricular Pacing Evaluation (HOBIPACE)
ichael Kindermann, MD,* Benno Hennen, MD,* Jens Jung, MD,† Jürgen Geisel, MD,‡
ichael Böhm, MD,* Gerd Fröhlig, MD*
omburg/Saar and Worms, Germany
OBJECTIVES The Homburg Biventricular Pacing Evaluation (HOBIPACE) is the first randomized
controlled study that compares the biventricular (BV) pacing approach with conventional
right ventricular (RV) pacing in patients with left ventricular (LV) dysfunction and a standard
indication for antibradycardia pacing in the ventricle.
BACKGROUND In patients with LV dysfunction and atrioventricular block, conventional RV pacing may yield
a detrimental effect on LV function.
METHODS Thirty patients with standard indication for permanent ventricular pacing and LV dysfunc-
tion defined by an LV end-diastolic diameter 60 mm and an ejection fraction 40% were
included. Using a prospective, randomized crossover design, three months of RV pacing were
compared with three months of BV pacing with regard to LV function, N-terminal
pro-B-type natriuretic peptide (NT-proBNP) serum concentration, exercise capacity, and
quality of life.
RESULTS When compared with RV pacing, BV stimulation reduced LV end-diastolic (9.0%, p 0.022)
and end-systolic volumes (16.9%, p 0.001), NT-proBNP level (31.0%, p 0.002), and the
Minnesota Living with Heart Failure score (18.9%, p 0.01). Left ventricular ejection fraction
(22.1%), peak oxygen consumption (12.0%), oxygen uptake at the ventilatory threshold
(12.5%), and peak circulatory power (21.0%) were higher (p 0.0002) with BV pacing. The
benefit of BV over RV pacing was similar for patients with (n  9) and without (n  21) atrial
fibrillation. Right ventricular function was not affected by BV pacing.
CONCLUSIONS In patients with LV dysfunction who need permanent ventricular pacing support, BV
stimulation is superior to conventional RV pacing with regard to LV function, quality of life,
and maximal as well as submaximal exercise capacity. (J Am Coll Cardiol 2006;47:1927–37)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.056© 2006 by the American College of Cardiology Foundation
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Sardiac resynchronization therapy has been evaluated
ainly in heart failure patients without the indication for
ntibradycardia pacing (1). Only in few controlled trials on
atients with atrial fibrillation and spontaneous (2) or
blation-induced bradycardia (2–4) the need for permanent
acing was not an exclusion criterion.
See page 1946
Although it is known that interventricular and intraven-
ricular impulse conduction and biventricular (BV) contrac-
ility and relaxation might be impaired (5–8) and adverse
yocardial remodeling might occur (9–11), the standard
pproach for patients with symptomatic bradycardia and
trioventricular (AV) malconduction is a pacing system that
ncludes a right ventricular (RV) apical lead. Right ventric-
From the *Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes,
omburg/Saar, Germany; †Innere Klinik I, Stadtkrankenhaus, Worms, Germany; and
Klinisch-Chemisches Zentrallabor, Universitätsklinikum des Saarlandes, Homburg/
aar, Germany.b
Manuscript received September 25, 2005; revised manuscript received December 1,
005, accepted December 5, 2005.lar outflow-tract pacing appears to convey a modest he-
odynamic benefit over RV apex pacing (12), but its role
till remains to be defined.
The detrimental effect of RV pacing is probably most
mportant in patients with pre-existing left ventricular (LV)
ysfunction (13–15) and may lead to aggravation of heart
ailure. In small uncontrolled trials, upgrading of RV pacing
o BV stimulation significantly improved functional status
nd LV performance in patients with congestive heart
ailure (16–18). However, the three published randomized
rials on BV pacing for patients with permanent atrial
brillation (2–4) showed only modest favorable effects of
V as compared with RV pacing. In view of these contro-
ersial data, the optimal pacing configuration for patients
ith LV systolic dysfunction who need permanent ventric-
lar pacing support is still unknown. This is the scope of the
omburg Biventricular Pacing Evaluation (HOBIPACE).
ETHODS
tudy population. Thirty-three patients with symptomatic
radycardia and impaired AV conduction that required
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Antibradycardic Biventricular Stimulation May 16, 2006:1927–37ermanent ventricular pacing were enrolled in the study.
nly patients with an LV end-diastolic diameter 60 mm
nd an LV ejection fraction 40% were included. Enroll-
ent was independent of etiology of LV dysfunction,
unctional status, and presence of sinus rhythm. After three
eaths during the study, complete data sets were available
or 30 patients. Baseline characteristics of these patients are
resented in Table 1. The study was approved by the local
thics committee (A¨rztekammer des Saarlandes No. 112/
8). All patients gave informed consent before device
mplantation.
evice implantation. Atriobiventricular devices were im-
lanted in 24 patients. The remaining six patients had
ermanent (duration 1 year) atrial fibrillation and got a
onventional dual-chamber pacemaker with the atrial port
onnected to the LV lead and the ventricular port receiving
he RV lead. Figure 1 gives an overview of the devices used.
he RV lead was attached to the RV septum in 17 cases; the
able 1. Pre-Operative Baseline Characteristics of the Study
atients (n  30)
ge (yrs) 69.6  8.1
ale gender, n (%) 23 (77)
YHA functional class 3.0  0.6
schemic etiology, n (%) 17 (57)
atients in sinus rhythm, n (%) 19 (63)
With AV block only, n (%) 11 (37)
With AV block and sinus bradycardia, n (%) 8 (27)
trial fibrillation and AV block, n (%)* 11 (37)
eft bundle branch block pattern, n (%)† 19 (63)
uration of the QRS interval (ms)† 174  42
V end-diastolic dimension (mm) 69.9  8.5
V end-systolic dimension (mm) 59.0  9.6
V end-diastolic volume (ml) 236.1  74.8
V end-systolic volume (ml) 177.3  68.7
V ejection fraction (%) 26.1  7.8
rade of mitral regurgitation 1.5  0.6
Includes six patients with permanent and five patients with persistent atrial
brillation; †refers to the intrinsic, unpaced QRS complex and includes ventricular
scape rhythms with left bundle branch block pattern in seven cases.
Abbreviations and Acronyms
AV  atrioventricular
BV  biventricular
DAVID  Dual Chamber and VVI Implantable
Defibrillator trial
HOBIPACE  Homburg Biventricular Pacing
Evaluation
LV  left ventricle/ventricular
LVS  left ventricular synchrony
LVS-SD  standard deviation of left ventricular
synchrony
MOST  Mode Selection Trial
NT-proBNP  N-terminal pro-B-type natriuretic
peptide
NYHA  New York Heart Association
PAVE  Post-Atrioventricular Nodal Ablation
Evaluation
RV  right ventricle/ventricularw
AV  atrioventricular; LV  left ventricular; NYHA  New York Heart
ssociation.emaining 13 leads were positioned in the RV apex. Left
entricular leads were introduced transvenously through a
oronary sinus venous branch and placed in a lateral,
osterior, or posterolateral position in 20 patients and in an
nterolateral position in 10 patients.
tudy protocol. HOBIPACE was a monocentric, prospec-
ive, randomized, single-blinded crossover comparison be-
ween RV and BV pacing. It was an investigator-driven trial
ithout industrial sponsorship. A flow chart of the study
rotocol is given in Figure 2. As it was the objective of the
tudy to evaluate the net effect of BV over RV pacing on the
ackground of optimal pharmacological therapy, the ran-
omization phase was preceded by a run-in period of three
onths, which was utilized to tailor drug therapy according
o guideline recommendations. In patients with atrial fibril-
ation, attempts were made to restore sinus rhythm using
irect current cardioversion and antiarrhythmic drug ther-
py including amiodarone. The run-in phase was also
ntended to detect and correct any device or lead-related
alfunction before patients entered the randomization
hase. To rule out early LV lead problems (dislodgement,
oss of capture, occasional diaphragmatic stimulation), de-
ices were programmed to the BV mode in the lead-in
eriod.
After three months, each patient was familiarized with
uality-of-life assessment and cardiopulmonary exercise
esting and underwent a test run of each procedure. The
esults of these tests were not used for further data analysis.
After randomization to one of the two pacing modes (RV
s. BV), the patients were followed for two three-month
tudy periods with crossover to the complementary pacing
ode after the first three-month interval. In patients with-
ut atrial fibrillation, the programmed AV delay was opti-
ized at the beginning of each study period using Ritter’s
pproach (19).
Outcome measures were assessed at the end of each
hree-month period. The study had three primary end
oints: LV end-systolic volume, LV ejection fraction, and
eak oxygen consumption. Functional class according to the
ew York Heart Association (NYHA), quality of life as
ssessed with the Minnesota Living with Heart Failure
uestionnaire (20), serum concentration of N-terminal pro-
-type natriuretic peptide (NT-proBNP), and parameters
erived from cardiopulmonary exercise testing and Doppler
chocardiography were classified as secondary end points.
Although the study was primarily designed to contrast
V to BV stimulation, a comparison was included between
re- and post-pacing echocardiographic parameters and
YHA functional classification. This analysis was intended
o investigate how RV pacing together with optimal phar-
acotherapy influences LV structure and function in pa-
ients with pre-existing LV dysfunction.
T-proBNP measurements. Venous blood samples were
aken from the resting and sitting patient at the beginning
f each follow-up visit. The samples were centrifuged
ithin 1 h and stored at 70°C for a maximum of one
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May 16, 2006:1927–37 Antibradycardic Biventricular Stimulationeek. Serum concentrations of NT-proBNP were measured
sing an Elecsys NT-proBNP sandwich electrochemilumi-
escent immunoassay carried out on an Elecsys 2010 bench
op analyzer (Roche Diagnostics, Mannheim, Germany).
chocardiography. All measurements were performed ac-
ording to the guidelines of the American Society of
chocardiography using M-mode recordings for unidimen-
ional parameters and Simpson’s biplane method for LV
olumes. Left ventricular muscle mass index was calculated
sing the formula of Devereux et al. (21). The LV hyper-
rophy index (22) was calculated as the sum of LV end-
iastolic septal and posterior wall thickness divided by
nd-diastolic diameter and given as a percentage.
Left and right ventricular heart cycle intervals were
easured by pulsed Doppler echocardiography as illustrated
Figure 1. Device types, number of first-time implantations, and
igure 2. Flow chart of the study protocol. *At three months, the patients
or further data analysis. AVDO optimization of the programmed atriove
cho  echocardiography; NT-proBNP  N-terminal pro-B-type natriuretic
ollow-up; QoL  quality of life as assessed by the Minnesota Living with Hen Figure 3. Two Doppler indexes of cardiac mechanical
unction were calculated for patients in sinus rhythm: the
ei index (23), which is inversely correlated to LV systolic
s well as diastolic function and the Z-ratio (24), which is
educed particularly in patients with electromechanical
synchrony.
Color Doppler tissue velocity imaging (frame rate
100/s) was used for quantification of LV synchrony. From
he apical four-chamber, two-chamber, and long-axis views,
six-basal and six-mid-segmental model was obtained in
he LV. Myocardial pulsed Doppler velocity profiles were
econstituted off-line from the tissue velocity imaging color
mages (25). In each of the 12 segments, the duration of
jection phase velocities 0.5 cm/s was measured and
ormalized to ejection time (Fig. 3). The average value of all
rade procedures. ICD  implantable cardioverter defibrillator.
rwent a trial procedure of QoL testing and CPET, which were not used
ular delay; BV biventricular; CPET cardiopulmonary exercise testing;unde
ntricpeptide; NYHA  New York Heart Association; PM-FU  pacemaker
art Failure questionnaire; RV  right ventricular.
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Antibradycardic Biventricular Stimulation May 16, 2006:1927–372 segments (LVS) and its standard deviation (LVS-SD)
ere calculated as indexes of LV synchrony.
Mitral valve regurgitation was graded from 0 to 4 using a
ombination of the proximal isovelocity surface area method
nd the vena contracta width approach (26). Left ventricular
p/dt was estimated from mitral regurgitation flow (27).
Echocardiography was performed using a Vingmed Vivid
ive ultrasound system capable of second harmonic imaging
nd equipped with a 2.5-MHz transducer (GE Medical
igure 3. Blood flow and tissue Doppler echocardiographic measurements
f heart cycle intervals and systolic left ventricular synchrony (LVS). a 
nterval between onset of the QRS complex and cessation of left ventric-
lar/right ventricular outflow; b  interval between onset of the QRS
omplex and start of AV inflow; c  interval between stop and start of
V inflow; d  part of the ejection phase with tissue velocities 0.5
m/s. CL, PET, ET, a, b, c, and d were directly measured. The other
arameters were calculated using the following formulae: IVRT  b  a;
VCT  c  IVRT  ET; DFT  CL  c; Tei index  (c  ET)/ET;
-ratio  100  (DFT  ET)/CL; LVS  100  (d/ET). AV 
trioventricular; CL  cycle length; DFT  diastolic filling time; ET 
jection time; IVCT  isovolumic contraction time; IVRT  isovolumic
elaxation time; PET  pre-ejection time interval between onset of the
RS complex and onset of left or right ventricular outflow.ystems, Milwaukee, Wisconsin). Echocardiographic data fere stored on magneto-optical hard disks and analyzed
ff-line on an EchoPac workstation (GE Medical Systems)
sing the average value of eight consecutive measurements
or each parameter.
ardiopulmonary exercise testing. All patients underwent
ymptom-limited cardiopulmonary exercise testing with
reath-by-breath gas exchange analysis using a MedGraph-
cs CPX/D spiroergometry system (Medical Graphics Cor-
oration, St. Paul, Minnesota). Patients performed bicycle
xercise in a 45°, semisupine position lying on an Ergomet-
ics 900EL reclining ergometer (Ergoline, Bitz, Germany).
fter adaptation to the mouthpiece in resting conditions,
orkload was increased continuously by 15 W/min (ramp
rotocol) starting at zero load. In each patient, maximum
orkload achieved, peak oxygen consumption, and oxygen
ptake at the ventilatory anaerobic threshold were mea-
ured. Peak oxygen consumption was defined as the highest
xygen uptake rate observed during the exercise test using a
unning average of seven breaths. The anaerobic threshold
as determined according to the V-slope method (28). Peak
irculatory power was calculated as the product of peak
xygen consumption and systolic arterial pressure (29). The
lopes of the linear regression between oxygen uptake (V˙O2)
ersus workload (aerobic work efficiency) (30) and minute
entilation versus carbon dioxide output (V˙CO2) (ventila-
ory efficiency) (31) were calculated.
tatistics. A two-tailed p value of 0.05 was considered
ignificant. Differences between pre-operative data, RV and
V pacing periods were assessed using a two-way univariate
nalysis of variance (ANOVA) for repeated measurements
ith post-hoc Student-Newman-Keuls test. The stimula-
ion mode (pre-operative vs. RV vs. BV pacing) was defined
s within-subjects factor. The randomization sequence
RV¡ BV vs. BV¡ RV) was entered as a between-groups
actor to allow for testing on treatment-period interaction
residual or carryover effect); ANOVA assumptions of
ormality and homoskedasticity were checked with the
olmogorov-Smirnov and Levene tests. Parameters that
et these assumptions are given as mean  1 SD. For
arameters, which passed the tests only after logarithmic
ransformation (e.g., NT-proBNP concentration), the geo-
etric mean with the back-transformed asymmetric stan-
ard deviation is given. Analysis of variance results were
djusted by Greenhouse-Geisser’s epsilon if a deviation
rom the sphericity assumption was found. Proportions and
requency distributions were analyzed using the chi-square
est. For multiple pairwise comparisons of relative drug
oses, the Friedman test was used. For the tissue-Doppler–
erived parameters of LV synchrony, the intra- and inter-
bserver repeatability of the measurement was calculated as
wice the SD of pairwise differences. Correlations between
arameters were assessed by calculating Pearsons’s product
oment correlation coefficient.
Sample size calculations were focused on primary end
oints assuming an absolute 4% increment in LV ejection
raction, a relative decrease in LV end-systolic volume of
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May 16, 2006:1927–37 Antibradycardic Biventricular Stimulation5%, and an increase in peak oxygen uptake of 1.5 ml/
in/kg with BV compared with RV pacing. Considering an
stimated coronary sinus lead failure rate of 10% and a
ost-to-follow-up rate of an additional 10%, the minimum
umber of patients required to detect a highly significant
p  0.01) difference between RV and BV pacing with a
ower of 90% was 21.
ESULTS
reatment period interaction. There was no significant
ffect of the randomization sequence (RV¡ BV vs. BV¡
V) on any of the parameters evaluated. Likewise, no
nteraction between randomization sequence and the
ithin-subjects factor could be detected.
tudy dropouts, re-operations, and premature crossover.
hree of 33 patients (9%) died during the course of the
tudy, one of them during the run-in period, the other two
atients after randomization to RV (n  1) and BV pacing
n  1), respectively. Causes of death were sudden cardiac
eath, fatal cerebral stroke, and suicide. Because end points
ould only be assessed in patients without missing data after
ompletion of both crossover phases, all results are based on
he 30 patients who completed the study.
Re-operations were required in three of these patients
10%) due to dislodgement of the LV lead in two cases and
ue to a device defect in another case. All corrections were
uccessfully performed during the run-in period. In one
atient who followed the BV ¡ RV randomization se-
uence, the RV phase had to be terminated prematurely
after one month) because of clinical deterioration. There
as no premature crossover or study termination in any
ther patient.
trial fibrillation management and device programming.
t study entry, six patients had permanent and five had
ersistent atrial fibrillation. During the lead-in phase, one
atient changed from sinus rhythm to atrial fibrillation.
hus, a total of six patients were considered amenable to
ardioversion and were treated with amiodarone and direct
urrent shock during the lead-in phase. In three patients,
trial fibrillation reoccurred within days, and sinus rhythm
as stable for the rest of the study in the remaining three.
o cardioversion attempt was made in the six patients with
ermanent atrial fibrillation who had undergone BV pace-
aker implantation without an atrial lead. As a result, nine
atients were in permanent atrial fibrillation at randomiza-
ion and for the rest of the study. Their devices were
rogrammed to RV or BV pacing only (depending on
andomization). In the remaining 21 patients with sinus
hythm, atrial-based RV or BV pacing was implemented.
he devices were programmed to an average LV pre-
xcitation of 19 14 ms. Rate adaption was turned on in 19
atients (63%) with chronotropic incompetence. Optimal
aced and sensed AV delays were significantly (p  0.010)
horter for RV pacing (paced: 142  40 ms; sensed: 81  i9 ms) than for BV stimulation (paced: 155  39 ms;
ensed: 99  36 ms).
ptimization of drug therapy. Due to bradycardia, beta-
lockers were underutilized before device implantation.
hree months thereafter, nearly every patient was on
edication with beta-blockers and angiotensin-converting
nzyme inhibitors or angiotensin II receptor blockers. Drug
herapy did not change during the two crossover periods
Table 2).
ffects of lead-in phase and RV pacing. In conjunction
ith optimized pharmacotherapy, RV pacing alone im-
roved LV end-diastolic (9%, p 0.017) and end-systolic
olume (10%, p  0.025) as well as LV ejection fraction
9%, p  0.048) over pre-implant conditions. New York
eart Association functional class was reduced by an
verage of 0.5 (p  0.003). Right ventricular pacing also
mproved the Tei index and the Z-ratio for the LV (Tei
ndex: p  0.010; Z-ratio: p  0.005) and RV (Tei index:
 0.001; Z-ratio: p  0.003). QRS duration (11%, p 
.002) and the pre-ejection intervals for the LV (17%, p
0.003) and RV (26%, p  0.002) were prolonged by
V pacing. Left ventricular diameters, LV muscle mass
ndex, LV hypertrophy index, cardiac index, LV dp/dt, left
trial diameter, degree of mitral regurgitation, and param-
ters of LV synchrony remained unchanged during RV
acing (Table 3).
mpact of BV pacing. PRIMARY END POINTS. All three
rimary end points for the comparison between RV and BV
acing were met (Figs. 4A, 4B, and 5). When compared
ith RV pacing, BV stimulation reduced LV end-systolic
olume by 17% (p  0.001), increased LV ejection fraction
y 22% (p 0.0002), and peak oxygen consumption by 12%
p  0.0003).
V function and structure. In comparison with RV pac-
ng, BV stimulation improved all parameters of LV dimen-
ion and function as well as left atrial diameters (Table 3).
he reduction in mitral regurgitation and LV muscle mass
able 2. Heart Failure Medication During the Course
f the Study
% of Patients
Taking
Pre-
Operative Run-In RVP BVP
CEI/ARBs 93 100 100 97
eta-blockers 67 100* 97† 97†
ldosterone
antagonists
43 57 60 57
iuretics 90 97 97 93
igitalis 37 47 57 53
miodarone 30 43 43 40
% of Max. Target Dose Achieved
(According to Guideline Recommendations)
eta-blockers 28  30 58  31‡ 67  28§ 65  34§
CEI/ARBs 52  41 58  39 64  48 67  48
p 0.005 vs. pre-operative; †p 0.02 vs. pre-operative; ‡p 0.01 vs. pre-operative;
p  0.001 vs. pre-operative.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor
locker; BVP  biventricular pacing; RVP  right ventricular pacing.ndex reached significance only for the pre-postoperative
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Antibradycardic Biventricular Stimulation May 16, 2006:1927–37omparison (Table 3). The improvement in LV function
ith BV versus RV pacing was paralleled by an increase in
ardiac index (16%, p  0.010) and LV dp/dt (27%,
 0.020). The decrease in LV mass index during BV
acing (p  0.010 vs. pre-operative; p  0.051 vs. RV
acing) was mirrored by an increase of 10% (p  0.002 vs.
V pacing) and 13% (p  0.001 vs. preoperative) in LV
ypertrophy index. Thus, reverse LV remodeling as induced
y BV pacing led to smaller LVs with thicker walls and
mproved systolic contraction.
Biventricular stimulation completely reversed the prolon-
ation of QRS width and LV pre-ejection period precipi-
ated by RV pacing. In comparison with both pre-implant
ata and RV pacing, BV stimulation reduced the difference
etween the RV and LV pre-ejection period (“interventric-
lar delay”—a surrogate parameter of interventricular dys-
ynchrony) by 83% (p  0.001) (Table 3). Right ventricular
re-ejection period was prolonged by BV pacing (p 0.001
s. pre-implant; p  0.026 vs. RV pacing). Switching from
V to BV pacing further improved Doppler indexes of LV
lectromechanical activation (Z-ratio, p 0.015) and global
V performance (Tei index, p  0.003). In contrast, RV
-ratio and Tei index were not different for RV and BV
acing.
T-proBNP concentration. The NT-pro-BNP serum
oncentrations were severely elevated in the study popula-
ion with a wide range for individual values during each of
he two pacing periods (Table 4). When compared with RV
Table 3. Comparison of Functional Class Acco
Echocardiographic, and Electrocardiographic P
After Three Months of RVP, and After Three
Parameters Pre-Ope
NYHA functional class 3.0 
LV end-diastolic diameter (mm) 69.9 
LV end-systolic diameter (mm) 59.0 
LV end-diastolic volume (ml) 236.1 
LV end-systolic volume (ml) 177.3 
LV ejection fraction (%) 26.1 
Left atrial diameter (mm) 55.0 
Grade of mitral regurgitation 1.5 
Cardiac index (l/min/m2) 2.15 
LV dp/dt (mm Hg/s) 509 
LV muscle mass index (g/m2) 185.1 
LV hypertrophy index (%) 30.8 
Duration of the QRS interval (ms) 174 
LV pre-ejection time (ms) 174 
RV pre-ejection time (ms) 125 
Pre-ejection time difference (ms) 49 
LV Z-ratio (%)§ 67.6 
LV Tei index§ 1.11 
RV Z-ratio (%)§ 75.1 
RV Tei index§ 0.85 
LV synchrony (%) 58.6 
LVS-SD (%) 20.6 
*/**/***p  0.05/p  0.01/p  0.001 for preoperative data vs
‡/‡‡/‡‡‡p  0.05/p  0.01/p  0.001 for preoperative data
BVP  biventricular pacing; LV  left ventricular; LVS-
Heart Association; RV  right ventricular; RVP  right veacing, BV stimulation reduced NT-proBNP concentration ey 31% (p  0.002). The reduction in NT-proBNP levels
as significantly correlated with the decrease in LV end-
iastolic (p  0.012) and end-systolic volumes (p  0.001),
he decrease in LV end-diastolic (p  0.001) and end-
ystolic diameters (p  0.008), the increase in LV hyper-
rophy index (p  0.032), and the increase in LV ejection
raction (p  0.004). Beyond this, NT-proBNP changes
rom RV to BV pacing were correlated with the improve-
ents in peak oxygen consumption (p  0.0002), peak
irculatory power (p  0.003), aerobic work efficiency (p 
.010), and ventilatory efficiency (p  0.002).
unctional class and quality of life. As compared with
re-implant values and RV pacing, BV stimulation im-
roved NYHA functional class by an average of 1.1 (p 
.001 vs. pre-implant) and 0.6 (p  0.015 vs. RV pacing)
Table 3). The Minnesota Heart Failure score was six points
ower with BV versus RV pacing (p  0.010) (Table 4). At
he end of the crossover phase, patients (unaware of the
rder of pacing modes) were asked for preferences of either
hree month period. Twenty patients (67%) preferred the
eriod with BV pacing (p 0.0002), two (7%) preferred the
eriod with RV pacing, and eight patients (26%) had no
reference.
xercise capacity. Beyond the increase in peak oxygen
onsumption, a higher maximum workload (p 0.015) and
eak circulatory power (p 0.0002) were achieved with BV
timulation as compared with RV pacing (Table 4). Switch-
ng from RV to BV pacing also improved submaximal
g to the NYHA Classification,
eters Before Device Implantation,
nths of BVP
RVP BVP
2.5  0.7† 1.9  0.6‡‡‡
68.7  9.1††† 64.9  8.9‡‡‡
58.1  11.1†† 53.6  11.1‡‡‡
215.6  76.2† 196.3  77.3‡‡‡
160.2  73.4††† 133.1  66.5‡‡‡
28.5  11.2††† 34.8  8.9‡‡‡
53.9  9.3† 51.7  8.1‡‡
1.4  0.7 1.1  0.5‡
2.00  0.40†† 2.31  0.42
619  138† 789  251‡
178.8  41.2 168.2  28.5‡‡
31.6  6.3†† 34.8  7.5‡‡‡
193  25††† 151  21‡‡‡
204  35† 184  33
157  36† 177  34‡‡‡
47  26††† 8  24‡‡‡
73.3  9.2† 77.6  6.8‡‡‡
0.91  0.38†† 0.72  0.24‡‡‡
83.1  10.2 84.2  7.8‡‡
* 0.55  0.39 0.49  0.26‡‡‡
61.1  15.1††† 79.2  8.8‡‡‡
17.8  6.2†† 13.5  5.2‡‡‡
; †/ ††/ †††p  0.05/p  0.01/p  0.001 for RVP vs. BVP;
VP; §Measured only in patients without atrial fibrillation.
standard deviation of LV synchrony; NYHA  New York
ar pacing.rdin
aram
Mo
rative
0.6**
8.5
9.6
74.8*
68.7*
7.8*
7.4
0.6
0.65
216
45.5
5.3
42**
37**
34**
31
9.7**
0.39**
10.1**
0.48**
14.9
7.4
. RVP
vs. Bxercise capacity: oxygen uptake and workload at the ven-
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May 16, 2006:1927–37 Antibradycardic Biventricular Stimulationilatory threshold rose by 13% (p  0.0002) and 16% (p 
.010), respectively. Aerobic work efficiency (V˙O2/
orkload-slope, p  0.038) and ventilatory efficiency
minute ventilation/V˙CO2-slope, p  0.023) were also
ncreased with BV over RV pacing. The respiratory ex-
hange ratio at maximum workload did not differ between
oth pacing modes (p  0.787), which underlines that
atients were driven to equal degrees of exhaustion during
oth crossover periods.
issue Doppler echocardiography. For tissue Doppler
arameters of left intraventricular synchrony, the coefficients
f intra-/interobserver repeatability were 3.3%/4.7% for
VS and 1.5%/2.6% for LVS-SD, respectively. While RV
acing did not change LV synchrony, BV stimulation was
ssociated with a highly significant increase of LVS and a
ecrease of LVS-SD (Figs. 6A and 6B). When switching
rom RV to BV pacing, the decrease of LVS-SD was
inearily correlated with both the reduction in LV end-
ystolic volume (p  0.0001) and the increase in LV
jection fraction (p 0.0002). Likewise, the decrease of LV
igure 4. (A and B) Summarized (box plots) and individual values (black
ircles) for left ventricular end-systolic volume (A) and left ventricular ejection
raction (B) before implantation of the study device (preop) and after three
onths of right (RVP) and biventricular (BVP) pacing. In the box plot graph,
he boundaries of the box indicate the 25th and 75th percentiles, the whiskers
ndicate the 10th and 90th percentiles, and the solid and dashed horizontal
ines mark the median and mean value, respectively.nd-systolic volume and the increase of LV ejection fraction
t
Fith BV stimulation showed a linear correlation with
VS-SD during RV pacing (p  0.001), indicating that
igher values of LVS-SD during RV pacing predicted more
enefit from BV stimulation. Between preoperative data and
V pacing, a linear correlation was found for the reduction
f LV end-systolic volume and LVS-SD (p  0.002).
eart cycle intervals. A systematic analysis of heart cycle
ntervals was restricted to patients in sinus rhythm. Com-
ared with pre-operative values, the main effect of RV
acing on left and right heart cycle intervals was a clear-cut
eduction of isovolumic contraction times by 46% (in LV:
 0.0003) and 63% (in RV: p  0.001) as well as a
rolongation of diastolic filling times by 15% (in LV: p 
.005; in RV: p 0.016) (Fig. 7). Although BV stimulation
ielded a greater reduction of LV isovolumic contraction
ime (62%, p  0.0002) and a greater prolongation of LV
lling time (21%, p  0.0005) than RV pacing, the
ifference between both pacing modes was not significant.
nly BV pacing led to a modest but significant (p  0.019)
rolongation of ejection times in both ventricles, which is
robably due to the increase in cardiac output. There was a
rend toward a prolongation of isovolumic relaxation times
ith RV pacing (18% in LV, p  0.495; 9% in RV,
 0.364), which was partly reversed by BV stimulation.
atient subgroups. Although patients with LV leads
laced in a lateral, posterolateral, or posterior position did
ot differ from patients with anterolateral LV leads regard-
ng improvements in LV volumes, ejection fraction, peak
xygen uptake, NT-proBNP, and quality of life, the in-
rease of LV synchrony when switching from RV to BV
acing was more pronounced in patients with coronary sinus
eads outside the anterolateral region (LVS increase: 21.3 
4.0% vs. 11.5  8.2%; p  0.050). In the 17 patients with
eptal RV leads, RV pacing significantly improved LV
ynchrony (LVS: 8.8  13.5%, p  0.043; LVS-SD
4.9 7.2%, p  0.033) as compared with pre-operative
alues. With RV apical leads (n  13), parameters of LV
ynchrony remained unchanged (LVS: 5.7  12.6%, p 
igure 5. Summarized (box plots) and individual values (black circles) for
eak oxygen consumption after three months of right (RVP) and biven-
ricular (BVP) pacing. For description of the box plot design, see legend to
igure 4.
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ead placement, RV pacing was able to reduce LV end-
ystolic volumes from pre-pacing values (27.2  36.5 ml,
 0.010) while apical RV pacing did not (3.8  30.1
l, p  0.695). If primary end point analysis was confined
o the 17 patients with RV septal leads, BV stimulation was
till significantly superior to RV pacing (LV ejection frac-
ion: p  0.001; LV end-systolic volume: p  0.003; peak
xygen uptake: p  0.005). Neither atrial fibrillation nor a
re-operative left bundle branch block pattern had a signif-
cant impact on the benefit of BV pacing.
ISCUSSION
his is not just a low-powered reduplication of earlier
ardiac resynchronization therapy trials in patients with
dvanced LV disease. Rather, HOBIPACE compares the
lternative of BV stimulation with standard RV pacing in
he setting of primary antibradycardia indication for patients
ith depressed LV function. While reducing the desynchro-
izing effect of conventional RV stimulation, BV pacing
as expected to be beneficial in patients with LV disease.
Indeed, BV pacing was superior to RV pacing because it
nduced significant reverse LV remodeling with a reduction
n LV end-diastolic and end-systolic volumes and an in-
rease in ejection fraction as compared with pacing the RV
lone. The relation between LV wall thickness and LV
iameter was increased by BV pacing, which—according to
he law of Laplace —implies a reduction in LV wall stress.
onsistent with reduced wall stress, NT-proBNP levels
ere lower during BV pacing as compared with RV pacing.
Of note, RV pacing alone offered a modest but significant
enefit in some parameters of LV and RV function when
ompared with pre-operative values. The improvement of
eart cycle intervals (reduction of isovolumic contraction
ime, increase of ventricular filling time) and of Doppler
chocardiographic indexes of ventricular function (Tei in-
ex, Z-ratio) that were achieved with RV pacing are
hought to be (at least in part) a consequence of better AV
equencing after dual-chamber pacemaker insertion for AV
Table 4. Effect of RVP Versus BVP on NT-p
and Exercise Capacity
Parameters
NT-proBNP concentration (pg/ml)*
MLHFQ score points
Peak oxygen consumption (ml/min/kg)
Peak circulatory power (mm Hgml/min/kg)
Ventilatory anaerobic threshold (ml/min/kg)
Maximum workload achieved (W)
Workload at ventilatory anaerobic threshold (W)
Slope of regression V˙O2 vs. workload (ml/min/W)
Slope of regression minute ventilation vs. V˙CO2 (l/l
RER at maximum workload (l/l)
*For NT-proBNP the geometric mean with the back-transfo
pacing (RVP) vs. biventricular pacing (BVP); ‡p  0.05 for
MLHFQ  Minnesota Living With Heart Failure qu
peptide; RER  respiratory exchange ratio, defined by V˙COlock (32). Because short-term studies on dual-chamber RV
L
dacing in congestive heart failure did not show any signif-
cant hemodynamic improvement (33), it is more likely,
owever, that RV septal pacing (in half of the patients),
ptimization of drug therapy, and cardioversion of atrial
brillation altogether account for the improvement achieved
y RV pacing.
igures 6. (A and B) Tissue-Doppler–derived parameters of left intraven-
ricular synchrony. LVS  duration of systolic ejection velocities 0.5
m/s averaged for 12 myocardial segments and given in percent of ejection
ime; LVS-SD  standard deviation of 12 segmental measurements of
P Release, Quality of Life,
RVP BVP
2,405 (743–7,783) 1,667 (521–5,334)†
31.2  20.7 25.3  18.1‡
12.5  2.9 14.0  3.0§
1,684  591 2,038  646§
8.0  2.0 9.0  1.7§
80.5  27.1 86.3  25.4‡
34.6  17.3 40.1  15.2‡
7.98  1.37 8.51  1.63‡
39.0  11.1 37.1  11.0‡
1.17  0.12 1.17  0.10
standard deviation is given; †p  0.01 for right ventricular
vs. BVP; §p  0.001 for RVP vs. BVP.
naire; NT-proBNP  N-terminal pro-B-type natriuretic
2; V˙CO2  carbon dioxide output; V˙O2  oxygen uptake.roBN
)
rmed
RVPVS; other abbreviations as in Figure 4. For description of the box plot
esign, see legend to Figure 4.
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May 16, 2006:1927–37 Antibradycardic Biventricular StimulationData from two controlled studies, the Dual Chamber and
VI Implantable Defibrillator (DAVID) trial (34) and the
ode Selection Trial (MOST) (35) indicate that RV
acing is associated with adverse outcome. In patients with
reserved LV function (MOST), RV pacing increased the
isk for heart failure hospitalization. In LV dysfunction
DAVID), the detrimental effect of RV stimulation was
ven worse with a risk increase of 60% for the combined end
oint of heart failure hospitalization or death. Although
hese studies were conducted in patients without AV block,
hey confirm observational studies that report adverse LV
emodeling during chronic RV pacing in patients with
ongenital AV block (9,11).
Despite the evidence for its detrimental effect, RV pacing
as remained the standard treatment of impaired AV
onduction. With the advent of dual-chamber pacing, AV
esynchronization was abolished, but LV desynchronization
y unphysiological impulse conduction from the RV apex
ontinues to be a problem that is unsolved. Because AV
onduction defects (including atrial fibrillation with slow
esponse) account for 50% of pacemaker implants and
ecause about one-third of pacemaker patients have LV
ystolic impairment (36), additional dysfunction induced by
V pacing is an issue of clinical importance.
Right ventricular outflow tract pacing is the most feasible
igure 7. Left and right heart cycle intervals before device implantation (
grey rectangles). DFT  diastolic filling time; ET  ejection time; IVC
re given in percent of cardiac cycle length. The p values are given in the fo
ersus biventricular pacing (middle), right ventricular pacing versus biventlternative to RV apical pacing (37) and appears to offer a omall hemodynamic improvement over RV apical pacing
12). In the present study, therefore, attempts were made to
ttach the RV lead to the interventricular septum in all
rimary implants. Using this approach, it was shown that
eptal but not apical RV pacing improved LV synchrony as
ell as LV end-systolic volume in comparison with pre-
perative data. However, even in the subgroup of patients
ith septal RV leads, LV function and exercise capacity
ere significantly better with BV than with RV pacing,
uggesting that BV stimulation is superior to any RV pacing
onfiguration.
In former studies on LV-based pacing, the acute hemo-
ynamic benefit of LV pacing alone was comparable to BV
acing (38), and it was suggested that LV pacing without an
dditional RV pacing lead would be the simplest and most
ffective approach for cardiac resynchronization therapy.
lthough transvenous LV lead technology has greatly im-
roved in recent years, it was not felt to be acceptable in the
resent study to randomize patients with AV block to LV
acing alone, because lead dislodgement rates and loss of
entricular capture are still higher for LV than for RV leads
39). Moreover, recent studies that compared LV and BV
acing yielded worse results for single-site LV pacing with
egard to LV filling time, exercise capacity, and provocation
rectangles), during right (stippled rectangles), and biventricular pacing
isovolumic contraction time; IVRT  isovolumic relaxation time. Values
ng order: pre-operative versus right ventricular pacing (top), pre-operative
r pacing (bottom). Data represent only patients in sinus rhythm.white
T f ventricular ectopy (40,41).
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Antibradycardic Biventricular Stimulation May 16, 2006:1927–37The results of the present study extend those of previous
rials on cardiac resynchronization therapy using BV pacing
n patients with LV dysfunction and increased QRS dura-
ion (1). HOBIPACE showed similar improvements in LV
unction, neurohumoral activation, functional class, quality
f life, and exercise capacity, but the setting was different; BV
acing was not tested against optimal pharmacological therapy,
ut was compared with RV pacing on top of optimal drug
herapy. This notion is still valid in view of 19 patients who
howed a left bundle branch block pattern before implantation.
owever, seven of these had ventricular escape rhythms in the
etting of AV block, which fulfilled the formal criteria of left
undle branch block.
It may be argued that RV pacing is just an experimental
odel for left bundle branch block and both have the same
mpact on LV activation and function (42). Despite a
imilar broadening of the QRS complex, however, RV
acing seems to have less detrimental effects on LV syn-
hrony than left bundle branch block (43). It seems,
herefore, unacceptable to extrapolate the benefits of BV
acing from heart failure patients with left bundle branch
lock to those who need ventricular pacing support. This is
hy dedicated studies are warranted.
So far, three published trials on BV versus RV pacing in
atients with permanent atrial fibrillation (2–4) yielded no
r only a modest benefit of BV pacing. Interpretation is
ampered by a 42% drop-out rate in the Multisite Stimu-
ation in Cardiomyopathies-Atrial Fibrillation (MUSTIC-
F) trial (2), which rendered the intention-to-treat analysis
egative and a dominant effect of rate control as compared
ith resynchronization in the Optimal Pacing Site Study
OPSITE) (3). The results of the Post-AV nodal Ablation
valuation (PAVE) (4), essentially a significant better
-min walk distance and ejection fraction with BV versus
V pacing six months after AV node ablation, support the
ndings of the present study. However, quality of life was
ot different between RV and BV pacing in the PAVE
tudy.
As in other trials on cardiac resynchronization, the effect
ize of BV pacing in HOBIPACE showed a wide scatter
rom absent to huge (Figs. 4 and 5). Because the implan-
ation of an atriobiventricular pacing system requires spe-
ialized skills, is time consuming and implies additional
isks, it cannot be recommended as a universal approach for
ach pacemaker clinic. It is an important issue for future
esearch to develop reliable predictors of a favorable re-
ponse to BV pacing. New echocardiographic techniques
ave yielded promising results (44), but their availability and
pplicability in clinical practice is still limited.
tudy limitations. HOBIPACE was an investigator-driven,
ingle-blind trial. Although a double-blinded design would
ave excluded any investigator bias, its feasibility in a device
rial seems questionable. Blinding of the investigator would
ave been jeopardized with one accidental look at the
lectrocardiogram, and the complex set of echocardio-
raphic parameters did not allow for shielding the electro-ardiographic tracing. Actually, parts of the study (measure-
ent of NT-proBNP by laboratory staff, self-assessed
uality-of-life questionnaire) were double-blinded and
ielded consistent results. The analysis of echocardiographic
ata was performed with unnamed storage media. Cardio-
ulmonary exercise testing used a protocol for standardized
otivation of the study patients and worked successfully, as
ay be inferred from identical respiratory equivalent ratios
t peak exercise for both pacing periods. Crossover designs
re prone to period and carryover effects. These could be
xcluded by the two-way ANOVA design that tested for
equence and interaction effects. As subgroup analyses in
mall studies are usually underpowered, negative findings
or subgroup comparisons in this study should be inter-
reted with caution.
onclusions. In patients with LV dysfunction who require
entricular pacing support for bradycardia with impaired
V conduction, the alternative approach of atriobiventricu-
ar or BV pacing should be considered. Biventricular rather
han RV pacing is associated with better LV function, better
uality of life, and better exercise capacity.
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linik für Innere Medizin III, Universitätsklinikum des Saarlandes, D
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